Marta Tato

1.4k total citations
33 papers, 1.0k citations indexed

About

Marta Tato is a scholar working on Infectious Diseases, Molecular Medicine and Epidemiology. According to data from OpenAlex, Marta Tato has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 15 papers in Molecular Medicine and 12 papers in Epidemiology. Recurrent topics in Marta Tato's work include Antibiotic Resistance in Bacteria (15 papers), Mycobacterium research and diagnosis (9 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). Marta Tato is often cited by papers focused on Antibiotic Resistance in Bacteria (15 papers), Mycobacterium research and diagnosis (9 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). Marta Tato collaborates with scholars based in Spain, United States and Italy. Marta Tato's co-authors include Rafael Cantón, Fernando Baquero, Teresa M. Coque, E Gómez-Mampaso, Jesús Fortün, Pilar Martín‐Dávila, María García-Castillo, Jordi Vilà, Yuly López and Patricia Ruíz-Garbajosa and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Clinical Microbiology.

In The Last Decade

Marta Tato

32 papers receiving 976 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marta Tato Spain 17 573 365 281 240 231 33 1.0k
Cristina Pitart Spain 19 633 1.1× 288 0.8× 378 1.3× 258 1.1× 267 1.2× 63 1.2k
Flávia Rossi Brazil 24 530 0.9× 469 1.3× 581 2.1× 233 1.0× 160 0.7× 92 1.3k
Nenad Maćešić Australia 17 577 1.0× 205 0.6× 275 1.0× 248 1.0× 178 0.8× 41 1.0k
D. Sofianou Greece 16 616 1.1× 228 0.6× 278 1.0× 168 0.7× 270 1.2× 39 1.1k
Sunita Mohapatra United States 6 706 1.2× 233 0.6× 344 1.2× 194 0.8× 202 0.9× 10 1.0k
María Ángeles Orellana Spain 20 428 0.7× 336 0.9× 370 1.3× 109 0.5× 251 1.1× 60 1.0k
Óscar Cuevas Spain 22 454 0.8× 496 1.4× 433 1.5× 132 0.6× 191 0.8× 42 1.2k
Vered Schechner Israel 15 638 1.1× 411 1.1× 534 1.9× 167 0.7× 233 1.0× 47 1.3k
An-Jing Kuo Taiwan 21 499 0.9× 278 0.8× 389 1.4× 135 0.6× 237 1.0× 33 1.1k
Tsigereda Tekle United States 15 693 1.2× 418 1.1× 256 0.9× 317 1.3× 221 1.0× 28 1.2k

Countries citing papers authored by Marta Tato

Since Specialization
Citations

This map shows the geographic impact of Marta Tato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Tato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Tato more than expected).

Fields of papers citing papers by Marta Tato

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Tato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Tato. The network helps show where Marta Tato may publish in the future.

Co-authorship network of co-authors of Marta Tato

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Tato. A scholar is included among the top collaborators of Marta Tato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Tato. Marta Tato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
López, Yuly, et al.. (2020). Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA. International Journal of Antimicrobial Agents. 56(3). 106082–106082. 4 indexed citations
3.
López-Roa, Paula, María Jesús Ruiz‐Serrano, Carlos Toro, et al.. (2020). Performance of Xpert MTB/RIF Ultra assay on respiratory and extra-respiratory samples in a high-resource setting with a low tuberculosis prevalence. Diagnostic Microbiology and Infectious Disease. 99(2). 115235–115235. 11 indexed citations
4.
López-Roa, Paula, Esteban Aznar, J. Cacho, et al.. (2020). Epidemiology of Non-Tuberculous Mycobacteria isolated from clinical specimens in Madrid, Spain, from 2013 to 2017. European Journal of Clinical Microbiology & Infectious Diseases. 39(6). 1089–1094. 16 indexed citations
5.
López, Yuly, et al.. (2019). Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis. PLoS ONE. 14(10). e0223326–e0223326. 10 indexed citations
6.
García-Castillo, María, Sergio García‐Fernández, Rosa Gómez-Gil, et al.. (2018). Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. International Journal of Antimicrobial Agents. 51(3). 511–515. 29 indexed citations
7.
García, Andrés González, Jesús Fortün, Enrique Navas, et al.. (2017). The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995–2013). Medicine. 96(26). e7219–e7219. 11 indexed citations
11.
Caballero, Juan de Dios, Rosa del Campo, Marta Tato, et al.. (2014). Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices. BMC Microbiology. 14(1). 335–335. 5 indexed citations
12.
López, Yuly, Marta Tato, Paula Espinal, et al.. (2014). In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci. Journal of Antimicrobial Chemotherapy. 70(1). 57–61. 13 indexed citations
13.
Ruíz-Garbajosa, Patricia, Tânia Curião, Marta Tato, et al.. (2013). Multiclonal dispersal of KPC genes following the emergence of non-ST258 KPC-producing Klebsiella pneumoniae clones in Madrid, Spain. Journal of Antimicrobial Chemotherapy. 68(11). 2487–2492. 43 indexed citations
14.
Tato, Marta, Yuly López, María Isabel Morosini, et al.. (2013). Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values. Diagnostic Microbiology and Infectious Disease. 78(3). 263–267. 43 indexed citations
15.
Tato, Marta, et al.. (2008). Entrevista clínica: modelos teóricos y un poco de práctica. 15(2). 167–171.
16.
Cobo, Javier, María‐Isabel Morosini, Vicente Pintado, et al.. (2007). Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase–producing Klebsiella pneumoniae epidemic clone. Diagnostic Microbiology and Infectious Disease. 60(3). 319–322. 43 indexed citations
17.
Tato, Marta, Teresa M. Coque, Vicente Pintado, et al.. (2007). Complex Clonal and Plasmid Epidemiology in the First Outbreak of Enterobacteriaceae Infection Involving VIM-1 Metallo- -Lactamase in Spain: Toward Endemicity?. Clinical Infectious Diseases. 45(9). 1171–1178. 96 indexed citations
18.
Tato, Marta, Rafael Cantón, Jesús Fortün, et al.. (2006). In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. International Journal of Antimicrobial Agents. 28(1). 75–78. 47 indexed citations
19.
Fortün, Jesús, Pilar Martín‐Dávila, Enrique Navas, et al.. (2005). Linezolid for the treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy. 56(1). 180–185. 167 indexed citations
20.
Galán, Juan Carlos, et al.. (2004). Fosfomycin and Rifampin Disk Diffusion Tests for Detection of Escherichia coli Mutator Strains. Journal of Clinical Microbiology. 42(9). 4310–4312. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026